We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

CERTEST BIOTEC

Certest Biotec, S.L. develops and manufactures IVD products in the human clinical testing field, including rapid test... read more Featured Products: More products

Download Mobile App





Certest Showcases Range of Rapid Tests and Real Time PCR Detection Kits at MEDICA 2021

By LabMedica International staff writers
Posted on 15 Nov 2021
Print article
Image: CerTest Rapid test (Photo courtesy of CerTest Biotec)
Image: CerTest Rapid test (Photo courtesy of CerTest Biotec)

CerTest Biotec (Zaragoza, Spain) showcased its range of rapid tests and real time PCR detection kits at the MEDICA 2021 trade fair held in Düsseldorf, Germany from 15-18th November. MEDICA is the world's largest medical trade fair for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals.

CerTest highlighted different products for infectious diseases, tumor and inflammation markers detection. The company also presented its range of enzymes for molecular biology and qPCR. CerTest highlighted its range of monoclonal antibodies with high sensitivity and specificity by using highly stable and pure immunogens and an in-house improved screening; liquid recombinant proteins with high purity and stability, through a process of cloning, expression, multi-step purification and buffer optimization; native antigens -inactivated- comprising a wide variety of bacteria and viruses; and molecular biology enzymes with high specific activity and high stability, with and w/o glycerol that are suitable for qPCR and RT-qPCR.

CerTest also presents its rapid test diagnostic products for detecting the presence of antigens with the immunochromatographic lateral flow technique. These products included rapid diagnostic tests for gastrointestinal, respiratory infectious diseases, and the detection of inflammatory or tumor markers in the GI tract. The company demonstrated why its rapid tests are easy to use, along with its robust and stable diagnostic devices that are designed to provide the best performance in the simplest way and at the lowest associated operational costs. Also on display was CerTest’s Turbilatex product line including turbidimetric assays based on the agglutination reaction between antibody-coated latex particles and the antigen in solution, as well as reagents that permit a high-sensitivity detection method to be obtained. The intended use for Turbilatex products is to detect and quantify the antigen present in human stool samples.

Additionally, CerTest showcased its VIASURE Real Time PCR Detection Kits that are designed for the diagnosis of infectious diseases caused by different pathogens in human samples. This product range is based on 5’ nuclease chemistry. This technology utilizes two primers and a hydrolysis probe and exploits the exonuclease activity of Taq DNA polymerase. During the amplification, the increase in the fluorescent signal is proportional to the quantity of target sequence present in the sample and could be measured on a wide range of Real Time PCR platforms. VIASURE Real Time PCR Detection Kit contains in each well all the necessary components for Real Time PCR assay in a stabilized format, which allows the shipment at room temperature.

Related Links:
CerTest Biotec 

Gold Supplier
Quality Control Material
Multichem U
New
Gold Supplier
Automatic Biochemistry Analyzer
Biossays C8
New
Silver Supplier
Receptor Destroying Enzyme
RDE II (Receptor Destroying Enzyme)
New
Automatic Photometer
JOLLY 103

Print article

Channels

Industry

view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.